Effect of marine collagen peptides on markers of metabolic nuclear receptors in type 2 diabetic patients with/without hypertension.
OBJECTIVE
To explore Effects of marine collagen peptides (MCPs) on markers of metablic nuclear receptors, i.e peroxisome proliferator-activated receptor (PPARs), liver X receptor (LXRs) and farnesoid X receptor (FXRs) in type 2 diabetic patients with/without hypertension. METHOD Study population consisted of 200 type 2 diabetic patients with/without hypertension and 50 healthy subjects, all of whom were randomly assigned to MCPs-treated diabetics (n = 50), placebo-treated diabetics (n = 50), MCPs-treated diabetics with hypertension (n=50), placebo-treated diabetics with hypertension (n = 50), and healthy controls (n = 50). MCPs or placebo (water-soluble starch) were given daily before breakfast and bedtime over three months. Levels of free fatty acid, cytochrome P450, leptin, resistin, adiponectin, bradykinin, NO, and Prostacyclin were determined before intervention, and 1.5 months, and 3 months after intervention. Hypoglycemia and the endpoint events during the study were recorded and compared among the study groups.


RESULTS
At the end of the study period, MCPs-treated patients showed marked improvement compared with patients receiving placebo. The protection exerted by MCPs seemed more profound in diabetics than in diabetics with hypertension. In particular, after MCPs intervention, levels of free fatty acid, hs-CRP, resistin, Prostacyclin decreased significantly in diabetics and tended to decrease in diabetic and hypertensive patients whereas levels of cytochrome P450, leptin, NO tended to decrease in diabetics with/without hypertension. Meanwhile, levels of adiponectin and bradykinin rose markedly in diabetics following MCPs administration.


CONCLUSIONS
MCPs could offer protection against diabetes and hypertension by affecting levels of molecules involved in diabetic and hypertensive pathogenesis. Regulation on metabolic nuclear receptors by MCPs may be the possible underlying mechanism for its observed effects in the study. Further study into its action may shed light on development of new drugs based on bioactive peptides from marine sources.
Zhu
Cui-Feng
CF
Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing 10083, China.
Li
Guan-Zhi
GZ
Peng
Hong-Bin
HB
Zhang
Fan
F
Chen
Yun
Y
Li
Yong
Y
D054392:Adipokines / Q000097:blood; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001920:Bradykinin / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D003094:Collagen / Q000627:therapeutic use*; D003577:Cytochrome P-450 Enzyme System / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D011464:Epoprostenol / Q000097:blood; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008386:Marine Biology; D008875:Middle Aged; D009569:Nitric Oxide / Q000097:blood; D010455:Peptides / Q000627:therapeutic use*; D011446:Prospective Studies; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism*
D054392:Adipokines; D015415:Biomarkers; D005230:Fatty Acids, Nonesterified; D010455:Peptides; D018160:Receptors, Cytoplasmic and Nuclear; D009569:Nitric Oxide; D003094:Collagen; D002097:C-Reactive Protein; D003577:Cytochrome P-450 Enzyme System; D011464:Epoprostenol; D001920:Bradykinin